Opinion|Videos|January 24, 2025
Choosing Bispecifics in 3L Treatment Setting R/R FL
Panelists discuss the use of bispecifics in the third-line setting for relapsed/refractory follicular lymphoma (R/R FL), exploring how often they are utilized and how bispecifics fit into the treatment paradigm compared with other options like chimeric antigen receptor (CAR) T, EZH2 inhibitors, and Bruton tyrosine kinase (BTK) inhibitors.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Moving into in the third-line setting, we have many options now including CAR T, bispecifics, EZH2 inhibitors, BTK inhibitors; let’s first focus on the bispecifics. Dr Khan, how often are you utilizing the bispecifics in the R/R FL setting? How do the bispecifics fit into your treatment paradigm compared with these other agents?
- What factors influence your decision when selecting between mosunetuzumab and epcoritamab?
- When selecting between mosunetuzumab and epcoritamab what are key factors to consider?
Advertisement
Related to this article
FDA has granted fast track designation to LYT-200 plus a hypomethylating agent in relapsed/refractory high-risk myelodysplastic syndromes.
Toon Van Gorp, MD, PhD, discusses key data with TUB-040 in platinum-resistant ovarian cancer and next steps for development.
Japan approved subcutaneous pembrolizumab and berahyaluronidase alfa across all indications for which intravenous pembrolizumab is approved in the country.
New research reveals how cancers carrying mutations in the p53 tumor-suppressor protein can hide those mutations from T cells.
Elise A. Chong, MD, discusses real-world liso-cel efficacy and safety, outpatient use, and future directions in relapsed/refractory mantle cell lymphoma.
Brad S. Kahl, MD, discusses TRIANGLE and EA4151 data reshaping ASCT use in frontline MCL, induction intensity, and high-risk disease strategies.
Mary Ann Anderson, MBBS, FRACP, FRCPA, PhD, discusses recent CLL approvals, BTK and BCL-2 inhibitor safety, and individualizing frontline therapy.
The top 5 OncLive TV videos of the week cover insights in NSCLC, large granular lymphocytic leukemia, ovarian cancer, and myelofibrosis.
Advertisement
Advertisement
Trending on OncLive
1
CLL Treatment Individualization Prompts Changes in Patient Evaluation and Care
2
Japan Approves Subcutaneous Pembrolizumab for All Approved Pembrolizumab Indications
3
FDA Grants Fast Track Designation to LYT-200 in R/R High-Risk MDS
4
Integrating Bispecific Antibodies Into Frontline Therapy for Newly Diagnosed Multiple Myeloma
5